Q2 FY2026 EarningsQ2 FY26 results presented a mixed profile against consensus: while Revenue remained at $0 as expected for a clinical-stage biotech, Net Loss was significantly higher than anticipated at -$36.4M vs. -$21.0M mean consensus. GAAP EPS of -$0.83 missed the consensus mean of -$0.60, primarily driven by a $10M development milestone payment for abdakibart and higher-than-expected stock-based compensation. The company's cash position of $472.2M provides a robust runway into 2029, a key positive for long-term clinical execution.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Avalo Therapeutics(AVTX) the EBIT is -31.52 M (-63.17%), Miss estimate;the EPS is -0.83 (+56.77%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.03B63.17%
-0.02B10.37%
-0.01B52.80%
EPSMiss expectations
-0.8356.77%
-0.599268.79%
-0.230812.02%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf